Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05956158 · ClinicalTrials.gov registry record · NA
RISE: A Remote Study of Insomnia Treatment in Crohn's Disease
A NA study of Insomnia and Crohn Disease, sponsored by Dartmouth-Hitchcock Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 83
- Enrollment target
- 1
- Study location
NCT05956158: Recruiting NA study of Insomnia and Crohn Disease, sponsored by Dartmouth-Hitchcock Medical Center.
NCT05956158 is a NA study of Insomnia and Crohn Disease that is actively recruiting participants, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 83 participants, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05956158, a NA study of Insomnia and Crohn Disease, is actively recruiting participants, sponsored by Dartmouth-Hitchcock Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 83 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess whether the investigators can treat insomnia in people with Crohn's disease, and if insomnia treatment can make other things better, like pain or inflammation.
Primary Outcome
Attrition rate will be based on the percentage of participants who have dropped out of the trial at different time points.
Conditions Studied
Interventions
- BEHAVIORAL Behavioral Treatment
- BEHAVIORAL Sleep Education Treatment
Study Locations (1)
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2023-11-28 |
| Est. Completion | 2026-11-30 |
| Phase | NA |
What NCT05956158 shows while recruiting
NCT05956158 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (51% lower).
The record links to 2 conditions, with Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Behavioral Treatment is the first listed.
NCT05956158 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT05956158 about?
NCT05956158 is a clinical study titled "RISE: A Remote Study of Insomnia Treatment in Crohn's Disease". The purpose of this study is to assess whether the investigators can treat insomnia in people with Crohn's disease, and if insomnia treatment can make other things better, like pain or inflammation.
What is the current status of trial NCT05956158?
This trial is currently recruiting. It is a NA study. The enrollment target is 83 participants. The study started on 2023-11-28. Estimated completion is 2026-11-30.
What conditions does trial NCT05956158 study?
This clinical trial studies the following conditions: Insomnia, Crohn Disease.
What interventions are being tested in trial NCT05956158?
The interventions under investigation include: Behavioral Treatment (BEHAVIORAL), Sleep Education Treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT05956158?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05956158 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insomnia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05956158's enrollment target sits among peer trials
83 72nd of 151 higher than 79 of 151 other Insomnia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insomnia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatments for Insomnia in Veterans With PTSD
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
mPATH for Low-income Older Adults
RECRUITING · NA
-
Accelerated Treatment for Co-occurring Insomnia, Nightmares, and PTSD
RECRUITING · NA
-
Adapted CBT-I for Adolescents With Insomnia : The DREAM-IT Study
RECRUITING · NA
-
Treatments in Women Veterans With Insomnia and PTSD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI